Indication
Recurrent WHO Grade II Glioma
6 clinical trials
8 products
Product
InfigratinibClinical trial
A Phase 1b/2, Multicenter, Open-Label Study of Oral Infigratinib in Pediatric Subjects With Advanced Solid and Central Nervous System (CNS) Tumors (Phase 1b) and in Subjects With Recurrent or Progressive Low-Grade Gliomas Harboring Selected FGFR1, FGFR2, or FGFR3 Alterations (Phase 2)Status: Withdrawn, Estimated PCD: 2022-12-16
Clinical trial
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive GlioblastomaStatus: Recruiting, Estimated PCD: 2024-09-01
Product
ChlorotoxinClinical trial
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 MutationsStatus: Completed, Estimated PCD: 2023-10-31
Product
BGB-290Product
TMZClinical trial
A Phase I Study of Multiple Doses of Neural Stem Cell-Based Oncolytic Virotherapy (NSC-CRAd-S-pk7) Administered Intracerebrally to Patients With Recurrent High-Grade GliomasStatus: Recruiting, Estimated PCD: 2025-08-07
Clinical trial
A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant GliomasStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGliomaStatus: Active (not recruiting), Estimated PCD: 2023-12-18